|
Daily Medical Update
Type 1 Diabetes Mellitus
Sunday, April 26, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Diabetes Care (2025) - Systematic Review and Meta-analysis
Key Findings
- Across 81 studies with 19,148 participants, diabetes technologies lowered hypoglycemia fear scores versus control (SMD -0.177; 95% CI -0.319 to -0.036).
- Technology use improved treatment satisfaction (SMD 0.429; 95% CI 0.206 to 0.653) and reduced diabetes distress/problem burden (SMD -0.265; 95% CI -0.363 to -0.166).
📋 Practice Implication: When choosing CGM or insulin delivery upgrades, clinicians should weigh patient-reported benefits alongside glycemic metrics, because technology appears to improve satisfaction and reduce diabetes-related distress.
|
Endocrine Practice (2025) - Systematic Review and Meta-analysis of Randomized Controlled Trials
Key Findings
- Automated insulin delivery increased time in range in both minoritized groups (MD 13.90%; 95% CI 9.64 to 18.16) and nonminoritized groups (MD 10.66%; 95% CI 9.12 to 12.21).
- HbA1c improved in both minoritized (MD -0.49%; 95% CI -0.69 to -0.29) and nonminoritized populations (MD -0.34%; 95% CI -0.46 to -0.23) without a significant rise in severe hypoglycemia or DKA.
📋 Practice Implication: Health systems can justify broader automated insulin delivery access for underserved populations, since benefit was at least as large in minoritized groups and did not appear to trade off against safety.
|
Endocrinology, Diabetes & Metabolism (2025) - Systematic Review and Meta-analysis
Key Findings
- Compared with standard care, the iLet bionic pancreas improved HbA1c (SMD -0.50; 95% CI -0.63 to -0.38), mean glucose (SMD -0.36; 95% CI -0.50 to -0.21), and time in target range (SMD 0.58; 95% CI 0.43 to 0.73).
- Adverse events were more frequent with iLet use (OR 15.48; 95% CI 8.07 to 29.70), while hypoglycemia was not significantly different (OR 2.22; 95% CI 0.83 to 5.94).
📋 Practice Implication: The iLet system is a plausible option for patients needing stronger glycemic improvement with less dosing burden, but rollout should include close monitoring for device-related adverse events until safety is better characterized.
|
Diabetic Medicine (2026) - Systematic Review and Meta-analysis
Key Findings
- Across 66 studies, screening programs were associated with a 23% lower rate of diabetic ketoacidosis at type 1 diabetes onset (95% CI 18% to 29%).
- Younger children with persistent and-or multiple islet autoantibodies had increased risk of progression to stage 3 type 1 diabetes, and time above 140 mg/dL was associated with progression during follow-up.
📋 Practice Implication: Pediatric screening programs should pair antibody testing with structured surveillance pathways, because the main clinical value is earlier detection with less DKA and better risk stratification after a positive screen.
|
Diabetic Medicine (2026) - Meta-analysis of Randomized Trials
Key Findings
- Hybrid closed-loop systems increased time in range by 8.8%, lowered mean glucose by 2.0 mg/dL, and reduced HbA1c compared with sensor-augmented pump therapy.
- They also reduced hyperglycemia exposure above 10 mmol/L by 7.8%, above 13.9 mmol/L by 3.63%, and above 16.7 mmol/L by 0.88%, with only modest hypoglycemia improvements.
📋 Practice Implication: For patients already using pump-based therapy who still have excess hyperglycemia or variability, upgrading from sensor-augmented pumping to hybrid closed-loop therapy has stronger support than continuing SAP alone.
|
|
💡
Summary
Recent high-significance evidence in type 1 diabetes was dominated by diabetes technology and screening studies rather than new disease-modifying therapies. Meta-analyses showed that automated and hybrid closed-loop systems improved time in range, HbA1c, and treatment experience, while youth screening programs reduced diabetic ketoacidosis at diagnosis and identified progression risk markers that can structure follow-up.
|
|